Evidence map›Paper›PMID 35631631›Full record

ArticlePharmaceutics2022

Swine as the Animal Model for Testing New Formulations of Anti-Inflammatory Drugs: Carprofen Pharmacokinetics and Bioavailability of the Intramuscular Route.

Lidia Gómez-Segura, Antoni Boix-Montañes, Mireia Mallandrich, Alexander Parra-Coca, José L Soriano-Ruiz, Ana Cristina Calpena, Álvaro Gimeno, David Bellido, Helena Colom

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Lidia Gómez-SeguraDepartment of Medicine and Animal Health, Faculty of Veterinary, Autonomous University of Barcelona, 08193 Bellaterra, Spain.ORCID 0000-0003-2635-554X
Antoni Boix-MontañesDepartment of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-0849-0492
Mireia MallandrichDepartment of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0001-9316-8459
Alexander Parra-CocaDepartment of Veterinary Medicine and Zootechnic, Faculty of Agriculture Sciences, University of Applied and Environmental Sciences, Bogota 111166, Colombia.
José L Soriano-RuizDepartment of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Granada, 18071 Granada, Spain.ORCID 0000-0001-9465-0538
Ana Cristina CalpenaDepartment of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-4989-4821
Álvaro GimenoDepartment of Animal Research, Animal House of Bellvitge, University of Barcelona, CCiT-UB, 08907 L'Hospitalet de Llobregat, Spain.
David BellidoDepartment of Separative Techniques, Scientific and Technological Centers, University of Barcelona, 08028 Barcelona, Spain.
Helena ColomDepartment of Pharmacy and Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain.
Institut de Nanociència i Nanotecnologia de la Universitat de BarcelonaBellvitge University Hospital · ESUniversidad de Granada · ESUniversitat Autònoma de Barcelona · ESUniversitat de Barcelona · ESUniversity of Applied and Environmental Sciences · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carprofen (CP) is a non-steroidal anti-inflammatory drug (NSAID) frequently used to treat respiratory diseases in numerous small animals, but also in large species. CP is a formidable candidate for further therapeutic research of human inflammatory diseases using the pig as an animal model. However, CP administration in swine is very uncommon and respective pharmacokinetics/bioavailability studies are scarce. A simultaneous population pharmacokinetic analysis after CP intravenous and intramuscular administrations in pigs has shown high extent and rate of absorption and a similar distribution profile with respect to man and other mammals. However, clearance and half-life values found in swine suggest a slower elimination process than that observed in man and some other animal species. Although not reported in other species, liver and kidney concentrations achieved at 48 h post-intramuscular administration in pigs were ten times lower than those found in plasma. Simulations pointed to 4 mg/kg every 24 h as the best dosage regimen to achieve similar therapeutic levels to those observed in other animal species. All these findings support the use of pig as an animal model to study the anti-inflammatory effects of CP in humans.

Indexed as

anti-inflammatory drugsbioanalysiscarprofenmass spectrometrypopulation pharmacokineticsswine animal modeltissue distribution

Identifiers

PMID35631631
PMCPMC9143053
OpenAlexW4280517178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.